Extra- Anatomical bypass applications still as an alternative in progressive aortoiliac occlusive disease manegement

Creative Commons License

Borulu F., Çalık E., Arslan Ü., Kılıç Y., Jalalzai İ., Erkut B., ...Daha Fazla

Indian Journal of Vascular and Endovascular Surgery, cilt.8, ss.310-316, 2021 (ESCI) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8
  • Basım Tarihi: 2021
  • Doi Numarası: 10.4103/ijves.ijves_66_21
  • Dergi Adı: Indian Journal of Vascular and Endovascular Surgery
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI)
  • Sayfa Sayıları: ss.310-316
  • Anahtar Kelimeler: Axillofemoral graft, femorofemoral graft, long-term graft patency, long-term limb salvage, long-term survival, COVERED ENDOVASCULAR RECONSTRUCTION, AORTOBIFEMORAL BYPASS, AXILLOFEMORAL BYPASS, EXTRAANATOMIC BYPASS, AORTIC BIFURCATION, EXPERIENCE, OUTCOMES, REVASCULARIZATION
  • Atatürk Üniversitesi Adresli: Evet

Özet

Aims: Extra-anatomical bypass (EAB) is still an important alternative treatment method in patients with aortoiliac occlusive disease (AIOD). Settings and Design: In this study, we assessed the results of EAB procedures, over a 22-year period, based on 30-day morbidity and mortality, 1st month, 1st, 3rd, and 5th year patient survival, primary patency, and limb salvage rates. Subjects and Methods: A retrospective review and analyze was performed on a single-center database of consecutive 46 patients who underwent femorofemoral or axillofemoral bypass grafting procedures from 1998 to 2020. All patients were called to followed up and were performed clinical examination and color duplex ultrasound (CDUS) evaluation for determination of graft patency. The surviving patients were followed-up for 5 years. Statistical Analysis Used: Five-year survival, graft patency, and limb salvage rates were calculated by the Kaplan-Meier method. Results: The 46 subjects included 25 (54.3%) femoral and 21 (45.7%) axillary bypass applications. The mean age was 64.2 +/- 12.8 years (28-82) and 36 were male (78.3%). Critical limb ischemia was the most accounted indication for EAB surgery (25/54.4%). The cumulative mortality rate was 34.8% at 5 years' period. The graft patency and limb salvage rates for femoral and axillary applications were 59.2% versus 57.4% and 86.4% versus 80% at 5 years, respectively. Conclusions: Femorofemoral and axillofemoral bypasses are suitable for patients with AIOD requiring revascularization for relief of symptoms or limb salvage, who are not candidates for endovascular therapy or who are at high risk for direct anatomical revascularization.